AMPE Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 mai 2024 @ 21:58):

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States...

Stats
Dagens volum	8 165.00
Gjennomsnittsvolum	60 762.00
Markedsverdi	274 567
EPS	$0 ( 2024-03-25 )
Neste inntjeningsdato	( $0 ) 2024-05-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0300
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-09	Buchi J Kevin	Buy	21 858	Common Stock
2023-06-08	Buchi J Kevin	Buy	25 000	Common Stock
2023-05-24	Martino Michael A	Buy	76 890	Common Stock
2023-05-16	Buchi J Kevin	Buy	32 534	Common Stock
2023-05-15	Buchi J Kevin	Buy	44 026	Common Stock

INSIDER POWER
100.00
Last 97 transactions
Buy: 6 813 241 \| Sell: 1 519 396

Ampio Pharmaceuticals Inc Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Ampio Pharmaceuticals Inc Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-10.66

FY	2023
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-10.66

FY	2022
Omsetning:	$0
Bruttogevinst:	$-2.08M (0.00 %)
EPS:	$-11.24

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.482

Financial Reports:

No articles found.

Ampio Pharmaceuticals Inc

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.

Sanntidsoppdatering for Ampio Pharmaceuticals Inc [AMPE]

Upcoming Earnings Alert